Discovery of New 1,4,6-Trisubstituted-1H-pyrazolo[3,4-b]pyridines with Anti-Tumor Efficacy in Mouse Model of Breast Cancer

• Published in: Pharmaceutics Vol. 15; no. 3; p. 787
• Main Authors: Georgiou, Maria, Lougiakis, Nikolaos, Tenta, Roxane, Gioti, Katerina, Baritaki, Stavroula, Gkaralea, Lydia-Evangelia, Deligianni, Elisavet, Marakos, Panagiotis, Pouli, Nicole, Stellas, Dimitris
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 27.02.2023; MDPI
• Subjects: anticancer agent; antiproliferative activity; Breast cancer; Chromatography; Cytotoxicity; in vivo; Kinases; purine analogues; pyrazolopyridine; Signal transduction
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15030787

Purine analogues are important therapeutic tools due to their affinity to enzymes or receptors that are involved in critical biological processes. In this study, new 1,4,6-trisubstituted pyrazolo[3,4-b]pyridines were designed and synthesized, and their cytotoxic potential was been studied. The new derivatives were prepared through suitable arylhydrazines, and upon successive conversion first to aminopyrazoles, they were converted then to 1,6-disubstituted pyrazolo[3,4-b]pyridine-4-ones; this served as the starting point for the synthesis of the target compounds. The cytotoxic activity of the derivatives was evaluated against several human and murine cancer cell lines. Substantial structure activity relationships (SARs) could be extracted, mainly concerning the 4-alkylaminoethyl ethers, which showed potent in vitro antiproliferative activity in the low μM level (0.75–4.15 μΜ) without affecting the proliferation of normal cells. The most potent analogues underwent in vivo evaluation and were found to inhibit tumor growth in vivo in an orthotopic breast cancer mouse model. The novel compounds exhibited no systemic toxicity; they affected only the implanted tumors and did not interfere with the immune system of the animals. Our results revealed a very potent novel compound which could be an ideal lead for the discovery of promising anti-tumor agents, and could also be further explored for combination treatments with immunotherapeutic drugs.